Venarus® (Venarus)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceHesperidin + DiosminHesperidin + Diosmin
Similar drugsTo uncover
  • ANGIORUS
    pills inwards 
    SYNTHESIS, OJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Venarus®
    pills inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Diovenges
    pills inwards 
    FORP, CJSC     Russia
    • Dosage form: & nbspfilm-coated tablets
    Composition:

    1 tablet contains:

    active ingredients: Hesperidin 50 mg, diosmin 450 mg; Excipients: cellulose microcrystalline 62.0 mg, carboxymethyl starch sodium (sodium starch glycolate) 27.0 mg, gelatin 3 1.0 mg, talc 6.0 mg, magnesium stearate 4.0 mg; excipients for the shell: hypromellose (hydroxypropylmethylcellulose 20.7 mg, macrogol 6000 (polyethylene glycol 6000) 3.38 mg, sodium lauryl sulfate 0.1 mg, magnesium stearate 1.24 mg, titanium dioxide 3.94 mg, iron oxide red 0.3 mg, iron oxide yellow 0.34 mg.

    Description:The tablets covered with a film membrane of orange-pink color, biconvex, oblong with rounded ends, with a risk. On the cross section, the core is from a grayish-yellow to a brownish-gray color.
    Pharmacotherapeutic group:Venotonizing and venoprotective agent
    ATX: & nbsp

    C.05.C.A.53   Diosmin in combination with other drugs

    Pharmacodynamics:Provides angioprotective and venotonic effect. Reduces the extensibility of veins, increases their tone and reduces venous congestion; reduces permeability, fragility of capillaries and increases their resistance; improves microcirculation and lymph drainage. With systematic use reduces the severity of clinical manifestations of chronic venous insufficiency of the lower extremities of an organic and functional nature.
    Pharmacokinetics:The main release of the drug occurs with feces. With urine, an average of about 14% of the drug intake is taken. The half-life is 11 hours. The drug is subject to active metabolism, which is confirmed by the presence of phenolic acids in the urine.
    Indications:Therapy of symptoms of venous-lymphatic insufficiency: pain, convulsions of the lower extremities, a feeling of heaviness and raspiraniya in the legs, "fatigue" of the legs. Therapy of manifestations of venous-lymphatic insufficiency: swelling of the lower extremities, trophic changes in the skin and subcutaneous tissue, venous trophic ulcers. Symptomatic therapy of acute and chronic hemorrhoids.
    Contraindications:Hypersensitivity to the active ingredients or excipients included in the preparation. It is not recommended to take the drug for lactating women.
    Pregnancy and lactation:

    Pregnancy

    Experiments on animals did not reveal teratogenic effects. To date, there have been no reports of any side effects when the drug is used by pregnant women.

    Breastfeeding period

    Due to the lack of data regarding the excretion of the drug in breast milk, it is not recommended to breast-feed women for taking the drug.

    Dosing and Administration:

    Inside.

    The recommended dose for venous-lymphatic insufficiency is 2 tablets per day (for one or two doses): morning, afternoon and / or evening, during meals. The duration of treatment can be several months (up to 12 months). In case of recurrence of symptoms, on the recommendation of a doctor, the course of treatment can be repeated.

    The recommended dose for acute hemorrhoids is 6 tablets per day: 3 tablets in the morning and 3 tablets in the evening for 4 days, then 4 tablets per day: 2 tablets in the morning and 2 tablets in the evening for the next 3 days.

    The recommended dose for chronic hemorrhoids is 2 tablets per day with meals.

    Side effects:

    The incidence of adverse reactions is as follows: very often (≥1 / 10 cases), often (≥1 / 100 and <1/10 cases) infrequently (≥1 / 1000 and <1/100 cases), rarely (≥1 / 10000 and <1/1000 cases) and very rarely (<1/10000 cases). Undesirable reactions, the frequency of development of which can not be estimated from available data, have the designation "frequency is unknown".

    From the central nervous system: rarely - dizziness, headache, general malaise; frequency is unknown - convulsions.

    From the gastrointestinal tract: often - diarrhea, dyspepsia, nausea, vomiting; infrequently - colitis; frequency unknown - abdominal pain. From the respiratory system, chest and mediastinum: the frequency is unknown - a sore throat, chest pain.

    From the skin: rarely - a rash, itching, hives; frequency unknown - dermatitis allergic, hyperemia, isolated edema of the face, lips, eyelids, in exceptional cases, angioedema.

    If any of the unwanted reactions listed in the manual is aggravated, or if you notice other undesirable reactions not listed in the instructions, inform your doctor.

    Overdose:

    Cases of overdose are not described.

    If an overdose occurs, seek medical help immediately.

    Interaction:

    Not noted.

    It is necessary to inform the attending physician of all medications taken.

    Special instructions:

    With exacerbation of hemorrhoids, the purpose of this drug does not replace the specific treatment of other anal disorders.

    Duration of treatment should not exceed the time specified in the section "Method of administration and dose".

    In the event that the symptoms do not disappear after the recommended course of therapy, a proctologic examination should be performed and the therapy used should be reviewed.

    In the presence of violations of venous circulation, the maximum effect of treatment is provided by combining therapy with a healthy (balanced) way of life: it is advisable to avoid long exposure to the sun,

    staying on legs, as well as reducing excess body weight. Hiking and, in some cases, wearing special stockings, helps improve blood circulation.

    Effect on the ability to drive transp. cf. and fur:Does not affect.
    Form release / dosage:Tablets, film-coated, 500 mg.
    Packaging:

    For 10 or 15 tablets, coated with a film sheath, into a contour cell package.

    By 2, 3, 4, 6, 7, 8, 9 contour cell packs together with the instruction for use are placed in a pack of cardboard.

    Storage conditions:At a temperature of no higher than 25 ° C. Keep out of the reach of children!
    Shelf life:4 years. Do not use after the expiration date.
    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-002282/08
    Date of registration:01.04.2008 / 27.07.2015
    Expiration Date:Unlimited
    The owner of the registration certificate:OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.01.2017
    Illustrated instructions
      Instructions
      Up